Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telomerase-directed molecular therapeutics.

W Nicol Keith1, Alan Bilsland, T R Jeffry Evans

  • 1Cancer Research UK Department of Medical Oncology, University of Glasgow, Cancer Research UK Beatson Laboratories, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK. n.keith@beatson.gla.ac.uk

Expert Reviews in Molecular Medicine
|February 28, 2004
PubMed
Summary

Cancer cells achieve immortality through the enzyme telomerase. Targeting telomerase offers a promising new strategy for developing novel anti-cancer therapies to combat malignant diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms.

British journal of cancer·2026
Same author

Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours.

Investigational new drugs·2026
Same author

Correction: Relative telomere length and senescence-associated inflammatory cytokines as blood-based prognostic markers in patients with advanced or resectable gastro-oesophageal adenocarcinoma.

British journal of cancer·2025
Same author

Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

Relative telomere length and senescence-associated inflammatory cytokines as blood-based prognostic markers in patients with advanced or resectable gastro-oesophageal adenocarcinoma.

British journal of cancer·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Malignant diseases pose significant challenges in modern medicine, with conventional treatments like surgery, chemotherapy, and radiotherapy showing limited success in advanced cancers.
  • Cancer cells exhibit unrestricted proliferation, a key characteristic distinguishing them from normal cells.
  • Understanding the molecular mechanisms behind uncontrolled cell growth is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To explore the role of telomerase in conferring immortality to cancer cells.
  • To identify telomerase as a potential molecular target for novel anti-cancer drug development.

Main Methods:

  • Review of current literature on cancer biology and therapeutic strategies.
  • Analysis of the molecular mechanisms underlying cancer cell proliferation and immortality.

Related Experiment Videos

  • Evaluation of telomerase as a therapeutic target based on its function in cancer cells.

    • Main Results:

    • Telomerase is identified as the enzyme responsible for conferring immortality upon cancer cells in most malignancies.
    • Cancer cells are critically dependent on telomerase activity for their survival and unrestricted proliferation.
    • This dependency makes telomerase an exceptionally attractive target for mechanism-based anti-cancer drug development.

    Conclusions:

    • Telomerase is a key factor in cancer cell immortality and survival.
    • Targeting telomerase presents a promising avenue for the development of next-generation cancer therapeutics.
    • Further research into telomerase inhibitors could lead to improved treatment outcomes for patients with advanced cancers.